NKIRU SMITH: Open Payments
NPI 1205332814 · ODENTON, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,096 in 78 payments from 14 companies in 2025. Trend: 2023 $980 · 2024 $1,598 · 2025 $2,096
Food & beverage: $2,087Education: $9
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 19 | $363 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $327 |
| Gilead Sciences, Inc. | 3 | $250 |
| Vanda Pharmaceuticals Inc. | 9 | $231 |
| Indivior Inc. | 8 | $220 |
| Axsome Therapeutics, Inc. | 8 | $205 |
| Otsuka America Pharmaceutical, Inc. | 3 | $176 |
| ABBVIE INC. | 4 | $85 |
| E.R. Squibb & Sons, L.L.C. | 3 | $76 |
| Lundbeck LLC | 2 | $55 |
Products named: CAPLYTA, Epclusa, REXULTI, SUBLOCADE, Auvelity, ARISTADA, LYBALVI, HETLIOZ.
Industry payments across MD — which companies pay providers there.
